November 16, 2023 eCOA Holds Annual Meeting in Denmark C-Path’s eCOA Consortium convened in Copenhagen, Denmark for its EU face-to-face meeting on Thursday, November 16. The eCOA...
November 16, 2023 Poster: C-Path’s Translational Therapeutics Accelerator: A Unique Solution to Successfully Bridge the Valley of Death in Academic Drug Discovery and Development
November 16, 2023 VCP Disease(s), an Integrated Approach to Neurodegenerative Disorders In this webinar from Critical Path Institute’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), speake
November 9, 2023 C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publica
November 7, 2023 C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology ype 1 Diabetes Consortium, along with external collaborators from Cardiff University and the University of Alberta, today announce
November 1, 2023-November 3, 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting Members of the CDRC team will join the CTOS at The Convention Centre Dublin in Ireland. The Connective Tissue Oncology Society...
October 26, 2023-October 27, 2023 C-Path Hosts Its Scientific Breakthrough Summit 2023 The summit featured presentations and panel discussions with C-Path collaborators from industry, academia, global regulatory...
October 26, 2023 C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading
October 25, 2023 C-Path Announces Significant Expansion in Neonatal RWD Project Details of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C. TUCSON, Ariz.,
